Home
Resources
Publications
Ciclopirox Inhibits Hepatitis B Virus Secretion by Blocking Capsid Assembly

Ciclopirox Inhibits Hepatitis B Virus Secretion by Blocking Capsid Assembly

Jung-Ah Kang, Songwon Kim, Minji Park, Hyun-Jin Park, Jeong-Hyun Kim, Sanghyeok Park, Jeong-Ryul Hwang, Yong-Chul Kim, Yoon Jun Kim, Yuri Cho, Mi Sun Jin, Sung-Gyoo Park

Nat Commun. 2019 May 16;10(1):2184.

PMID: 31097716

Abstract:

Chronic hepatitis B virus (HBV) infection can cause cirrhosis and hepatocellular carcinoma and is therefore a serious public health problem. Infected patients are currently treated with nucleoside/nucleotide analogs and interferon α, but this approach is not curative. Here, we screen 978 FDA-approved compounds for their ability to inhibit HBV replication in HBV-expressing HepG2.2.15 cells. We find that ciclopirox, a synthetic antifungal agent, strongly inhibits HBV replication in cells and in mice by blocking HBV capsid assembly. The crystal structure of the HBV core protein and ciclopirox complex reveals a unique binding mode at dimer-dimer interfaces. Ciclopirox synergizes with nucleoside/nucleotide analogs to prevent HBV replication in cells and in a humanized liver mouse model. Therefore, orally-administered ciclopirox may provide a novel opportunity to combat chronic HBV infection by blocking HBV capsid assembly.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP67587240	Ciclopirox Related Compound C		67587-24-0	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: